The COVID pandemic ushered mRNA vaccines into the spotlight, and the technology has even greater potential. Here’s what to ...
Once considered cellular junk, non-coding RNAs are emerging as key players in everything from brain development to cancer — ...
When people talk about transformative technologies today, the conversation usually moves quickly to artificial intelligence, ...
Investor's Business Daily on MSN
Sarepta surges as it takes on Novartis' $12 billion muscular dystrophy buyout
Sarepta stock popped Wednesday after the company reported promising results for its gene-silencing tech in two forms of ...
Existing bacteria and archaea still our universal common ancestor’s ribosomal hibernation defense mechanism when nutrients ...
Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...
CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 vaccine in more than 30 countries. Payn ...
A research team from The Hong Kong University of Science and Technology (HKUST) has made an advance in understanding the molecular machinery of RNA silencing. The team uncovered how the human enzyme ...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results